利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

32 条记录 (耗时 0.06 秒)

    Systems and methods for performing hemodialysis
    1.
    发明授权
    Systems and methods for performing hemodialysis 有权
    用于进行血液透析的系统和方法

    公开(公告)号：US08961789B2

    公开(公告)日：2015-02-24

    申请号：US12338052

    申请日：2008-12-18

    申请人： Randolph H. Watkins ,  Steven J. Wurgler ,  Shincy Maliekkal ,  Sujatha Karoor ,  Katrina Smith

    发明人： Randolph H. Watkins ,  Steven J. Wurgler ,  Shincy Maliekkal ,  Sujatha Karoor ,  Katrina Smith

    IPC分类号： B01D63/00 ,  C02F1/44 ,  A61M1/34 ,  B01D63/16 ,  B01D65/08 ,  A61M1/26

    CPC分类号： A61M1/1623 ,  A61M1/26 ,  A61M1/265 ,  A61M1/3472 ,  A61M1/3479 ,  B01D63/16 ,  B01D65/08 ,  B01D2315/02 ,  B01D2321/2033

    摘要： Systems and methods for performing hemodialysis to remove metabolic waste from the blood of a patient are disclosed. The systems and methods preferably comprise at least one blood processing apparatus that receives whole blood from a patient. Cellular blood components are removed from the whole blood by hemofiltration, to provide filtered plasma comprising metabolic waste that is substantially reduced of blood cells. The cellular blood components may be returned to the patient. The filtered plasma comprising waste may be removed from the blood processing apparatus through a waste path for further processing in a separate apparatus, or in the same apparatus in a second stage processing procedure to remove metabolic waste components and excess water from the plasma by hemodialysis. At least one of the hemofiltration and hemodialysis processing apparatus comprises a Taylor vortex-enhanced separation apparatus.

    摘要翻译： 公开了用于进行血液透析以从患者的血液中除去代谢废物的系统和方法。 该系统和方法优选地包括从患者接收全血的至少一个血液处理装置。 通过血液滤过从全血中除去细胞血液成分，以提供包含基本上减少血细胞的代谢废物的过滤血浆。 细胞血液成分可以返回给患者。 包含废物的过滤等离子体可以通过废物路径从血液处理设备中除去，以便在单独的设备中进行进一步处理，或者在第二阶段处理过程中的相同装置中，通过血液透析从血浆中除去代谢废物成分和过量的水。 血液透析和血液透析处理装置中的至少一个包括泰勒涡旋增强分离装置。

    SYSTEMS AND METHODS FOR PERFORMING HEMODIALYSIS
    2.
    发明申请
    SYSTEMS AND METHODS FOR PERFORMING HEMODIALYSIS 有权
    用于执行肝细胞分析的系统和方法

    公开(公告)号：US20100108606A1

    公开(公告)日：2010-05-06

    申请号：US12338052

    申请日：2008-12-18

    申请人： Randolf H. Watkins ,  Steven J. Wurgler ,  Shincy Maliekkal ,  Sujatha Karoor ,  Katrina Smith

    发明人： Randolf H. Watkins ,  Steven J. Wurgler ,  Shincy Maliekkal ,  Sujatha Karoor ,  Katrina Smith

    IPC分类号： B01D61/24

    CPC分类号： A61M1/1623 ,  A61M1/26 ,  A61M1/265 ,  A61M1/3472 ,  A61M1/3479 ,  B01D63/16 ,  B01D65/08 ,  B01D2315/02 ,  B01D2321/2033

    摘要： Systems and methods for performing hemodialysis to remove metabolic waste from the blood of a patient are disclosed. The systems and methods preferably comprise at least one blood processing apparatus that receives whole blood from a patient. Cellular blood components are removed from the whole blood by hemofiltration, to provide filtered plasma comprising metabolic waste that is substantially reduced of blood cells. The cellular blood components may be returned to the patient. The filtered plasma comprising waste may be removed from the blood processing apparatus through a waste path for further processing in a separate apparatus, or in the same apparatus in a second stage processing procedure to remove metabolic waste components and excess water from the plasma by hemodialysis. At least one of the hemofiltration and hemodialysis processing apparatus comprises a Taylor vortex-enhanced separation apparatus.

    摘要翻译： 公开了用于进行血液透析以从患者的血液中除去代谢废物的系统和方法。 该系统和方法优选地包括从患者接收全血的至少一个血液处理装置。 通过血液滤过从全血中除去细胞血液成分，以提供包含基本上减少血细胞的代谢废物的过滤血浆。 细胞血液成分可以返回给患者。 包含废物的过滤等离子体可以通过废物路径从血液处理设备中除去，用于在单独的设备中进行进一步处理，或者在第二阶段处理程序中的相同装置中，通过血液透析从血浆中除去代谢废物成分和过量的水。 血液透析和血液透析处理装置中的至少一个包括泰勒涡旋增强分离装置。

    METHOD AND COMPOSITION FOR REMOVING UREMIC TOXINS IN DIALYSIS PROCESSES
    4.
    发明申请
    METHOD AND COMPOSITION FOR REMOVING UREMIC TOXINS IN DIALYSIS PROCESSES 有权
    在脱水过程中去除尿毒素的方法和组合物

    公开(公告)号：US20130213891A1

    公开(公告)日：2013-08-22

    申请号：US13745388

    申请日：2013-01-18

    申请人： Sujatha Karoor

    发明人： Sujatha Karoor

    IPC分类号： A61M1/14 ,  A61M1/28

    CPC分类号： A61M1/3687 ,  A61M1/14 ,  A61M1/1694 ,  A61M1/1696 ,  A61M1/267 ,  A61M1/28 ,  A61M1/284 ,  A61M1/287 ,  A61M1/3679 ,  A61M2209/088 ,  B01J20/0292 ,  B01J20/06 ,  B01J20/20 ,  B01J20/24 ,  B01J20/28052 ,  B01J2220/62

    摘要： A dialysis system comprising: a sorbent cartridge in fluid communication with at least one of a patient or a dialyzer, the sorbent cartridge including a housing having a zirconium phosphate layer followed by at least one of a urease layer, a zirconium oxide layer, or a carbon layer; a storage container in fluid communication with the sorbent cartridge; a pump in fluid communication sorbent cartridge and the storage container; and a control unit in operable communication with the pump, wherein the control unit is programmed to cause the pump to pump a dialysis fluid to flow (i) in a first direction through the sorbent cartridge, wherein the zirconium phosphate layer is contacted by the dialysis fluid before the at least one of the urease layer, zirconium oxide layer or carbon layer and (ii) in a second direction, reverse from the first direction, through the sorbent cartridge wherein the at least one of the urease layer, zirconium oxide layer or carbon layer is contacted by the dialysis fluid before the zirconium phosphate layer.

    摘要翻译： 一种透析系统，包括：与患者或透析器中的至少一个流体连通的吸附剂盒，所述吸着剂盒包括具有磷酸锆层的壳体，其后是脲酶层，氧化锆层或 碳层; 与吸附剂盒流体连通的储存容器; 流体连通吸附剂盒中的泵​​和储存容器; 以及与所述泵可操作地连通的控制单元，其中所述控制单元被编程为使所述泵泵送透析流体沿着第一方向流过所述吸附剂筒，其中所述磷酸锆层与所述透析接触 在尿素酶层，氧化锆层或碳层中的至少一个之前的流体和（ii）沿与第一方向相反的第二方向通过吸附剂盒，其中脲酶层，氧化锆层或 在磷酸锆层之前，碳层与透析液接触。

    DIALYSIS SOLUTIONS CONTAINING PYROPHOSPHATES
    7.
    发明申请
    DIALYSIS SOLUTIONS CONTAINING PYROPHOSPHATES 有权
    包含磷酸盐的透析溶液

    公开(公告)号：US20090098215A1

    公开(公告)日：2009-04-16

    申请号：US11871018

    申请日：2007-10-11

    申请人： Bruce L. Riser ,  Paul Zieske ,  Sujatha Karoor ,  Himanshu D. Patel

    发明人： Bruce L. Riser ,  Paul Zieske ,  Sujatha Karoor ,  Himanshu D. Patel

    IPC分类号： A61K33/42 ,  A61P7/08

    CPC分类号： A61K33/42 ,  A61L2/0011 ,  A61L2/0017 ,  A61L2/0023 ,  A61M1/1672 ,  A61M1/1674 ,  A61M1/287

    摘要： Dialysis solutions comprising pyrophosphates and methods of making and using the dialysis solutions are provided. In an embodiment, the present disclosure provides a dialysis solution comprising a stable and therapeutically effective amount of pyrophosphate. The dialysis solution can be sterilized, for example, using a technique such as autoclave, steam, high pressure, ultra-violet, filtration or combination thereof. The dialysis solution can be in the form of a concentrate.

    摘要翻译： 提供了包含焦磷酸盐的透析溶液以及制备和使用透析溶液的方法。 在一个实施方案中，本公开提供了包含稳定和治疗有效量的焦磷酸盐的透析溶液。 透析溶液可以例如使用高压釜，蒸汽，高压，紫外线，过滤或其组合的技术进行灭菌。 透析溶液可以是浓缩物的形式。

    PERITONEAL DIALYSIS SOLUTIONS COMPRISING GLUCOSE POLYMERS
    9.
    发明申请
    PERITONEAL DIALYSIS SOLUTIONS COMPRISING GLUCOSE POLYMERS 有权
    包含葡萄糖聚合物的PERITONEAL DIALYSIS SOLUTIONS

    公开(公告)号：US20120238525A1

    公开(公告)日：2012-09-20

    申请号：US13419701

    申请日：2012-03-14

    申请人： John Kenneth Leypoldt ,  Clifford J. Holmes ,  Sujatha Karoor ,  Catherine M. Hoff ,  Leo Martis ,  Rahul Tandon

    发明人： John Kenneth Leypoldt ,  Clifford J. Holmes ,  Sujatha Karoor ,  Catherine M. Hoff ,  Leo Martis ,  Rahul Tandon

    IPC分类号： A61K31/715 ,  A61P13/12 ,  A61K31/718

    CPC分类号： A61K31/717 ,  A61K31/716 ,  A61K31/718 ,  C08L3/02

    摘要： Peritoneal dialysis solutions including a glucose polymer and methods of using the dialysis solutions are disclosed herein. In a general embodiment, the peritoneal dialysis solution includes a glucose polymer in an amount to provide an increased ultrafiltration fluid volume for a given amount of carbohydrate absorbed compared to conventional dialysis solutions containing icodextrin as the active pharmaceutical ingredient. The increased ultrafiltration fluid volume for a given amount of carbohydrate absorbed is obtained by providing specific combinations of weight-average molecular weight, polydispersity index and concentration of the glucose polymer in the dialysis solution.

    摘要翻译： 本文公开了包括葡萄糖聚合物的腹膜透析溶液和使用透析溶液的方法。 在一般实施方案中，腹膜透析溶液包含葡萄糖聚合物，其含量与给定量的碳水化合物相比提供了增加的超滤流体体积，与常规含有作为活性药物成分的伊曲诺白蛋白的透析溶液相比。 通过提供透析溶液中葡萄糖聚合物的重均分子量，多分散指数和浓度的特定组合，可以获得给定量的碳水化合物吸收增加的超滤液体积。